UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001337
Receipt number R000001625
Scientific Title Photodynamic diagnosis of bladder cancer using fluorescence cystoscopy with 5-aminolevulinic acid (5-ALA)
Date of disclosure of the study information 2008/08/27
Last modified on 2015/04/24 14:38:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Photodynamic diagnosis of bladder cancer using fluorescence cystoscopy with 5-aminolevulinic acid (5-ALA)

Acronym

Photodynamic diagnosis of bladder cancer

Scientific Title

Photodynamic diagnosis of bladder cancer using fluorescence cystoscopy with 5-aminolevulinic acid (5-ALA)

Scientific Title:Acronym

Photodynamic diagnosis of bladder cancer

Region

Japan


Condition

Condition

Superficial bladder cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the value of the photodynamic diagnosis (PDD) of superficial bladder cancer using fluorescence cystoscopy with 5-aminolevulinic acid (5-ALA) and transurethral resection of bladder tumor (TURBT) guided PDD.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

Number of side effect by grade
Incidence of side effect by grade

Key secondary outcomes

Diagnostic accuracy: Comparison between fluorescence guide-cystoscopy mediated by 5-ALA and histological findings of collected tissue by biopsy or TURBT


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine Device,equipment Maneuver

Interventions/Control_1

5-aminolevulinic acid (5-ALA) (unapproved drug by Japanese pharmaceutical affairs law) dissolved in 50mL of 5% glucose solution.
5-ALA solution was administered either way of following:
Orally(1.0g/50mL); 180-240minutes before operation
Instilled intravesically(1.5g/50mL); 90-120 minutes before operation.
For fluorescence excitation a blue light source (D-LIGHT System, Karl Storz Endoscopy Japan K.K.) was used.
Under white and fluorescence light guidance outputted by light source apparatus (D-Light AF System) and videocamera system (Endovision TELECAM SL/IPM-PPD System), tumor locations were recorded, cold cup biopsies were taken and tumors were resected.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

patient who has primary and recurrent superficial bladder cancer indicated for transurethral biopsy of bladder mocosa (TU-biopsy) and/or transurethral resection of bladder tumor (TURBT)

Key exclusion criteria

patient who has potential complication of local disorder and systematic absorption of 5-ALA such as solar photosensitivity and liver dysfunction

Target sample size

165


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Taro Shuin

Organization

Kochi Medical School

Division name

Department of Urology, Kochi Medical School

Zip code


Address

Kohasu, Oko, Nankoku, Kochi, Japan

TEL

088-880-2402

Email

shuint@kochi-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Keiji Inoue

Organization

Kochi Medical School

Division name

Department of Urology, Kochi Medical School

Zip code


Address

Kohasu, Oko, Nankoku, Kochi, Japan

TEL

088-880-2402

Homepage URL


Email

keiji@kochi-u.ac.jp


Sponsor or person

Institute

Department of Urology, Kochi Medical School

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

-


Other related organizations

Co-sponsor

Ethical committee, Kochi Medical School

Name of secondary funder(s)

Kohasu, Oko, Nankoku, Kochi, Japan


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 08 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 02 Month 24 Day

Date of IRB


Anticipated trial start date

2008 Year 01 Month 01 Day

Last follow-up date

2013 Year 08 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 08 Month 27 Day

Last modified on

2015 Year 04 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001625


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name